Naltrexone - Pharmacology
Research News and Information

Sunday, November 22, 2009

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.

30 Oct 2009 Preclinical investigations utilizing murine experimental auto-immune encephalomyelitis (EAE), as well as clinical observations in patients with multiple sclerosis (MS), may suggest alteration of endogenous opioid systems in MS. In this study we used ... Read more...

Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion.

30 Oct 2009 BACKGROUND: Methadone is an opioid agonist often given to manage acute and chronic pain. We sought to determine whether methadone compared with morphine dose dependently reduces myocardial infarct size (IS) and whether the mechanism is delta-opioid ... Read more...

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.

10 Aug 2009 The opioid growth factor (OGF) regulates cell proliferation of human cancer cells through the cyclin-dependent kinase inhibitory pathway, with mediation of this action by the OGF receptor (OGFr). The ubiquity of the OGF-OGFr axis in human cancer is ... Read more...

Latest indexed articles for 'Naltrexone - Pharmacology'

These are the very latest articles for this heading:

• Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. 30 Oct 2009
• Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. 30 Oct 2009
• Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. 10 Aug 2009
• Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. Aug 2009
• Appetitive motivational experience during adolescence results in enhanced alcohol consumption during adulthood. 30 Jul 2009
• Opioid antagonists block the acquisition of ethanol-mediated conditioned tactile preference in infant rats. 30 Jul 2009
• Naltrexone for the treatment of obesity: review and update. 30 Jul 2009
• Effects of dehydroepiandrosterone sulfate on the conversion of corticosterone into 11-dehydrocorticosterone in stress: a regulatory scheme. 19 Jul 2009
• Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway. 16 Jul 2009
• Methylnaltrexone. 13 Jul 2009
• Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. 13 Jul 2009
• 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice. 3 Jul 2009
• Methylnaltrexone reduced body weight gain in ob/ob mice. 29 Jun 2009
• Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice. 29 Jun 2009
• Prodynorphin gene deficiency potentiates nalbuphine-induced behavioral sensitization and withdrawal syndrome in mice. 23 Jun 2009
• Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice. 22 Jun 2009
• Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5'-guanidinonaltrindole-induced scratching models in mice: behavioral and neuroanatomical evidence. 19 Jun 2009
• Role of the opioid system in incentive downshift situations. 12 Jun 2009
• Naltrexone fails to increase pain affect in response to inflammatory pain in a novel escape/avoidance paradigm. 4 Jun 2009
• Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. Jun 2009

See a longer list of these articles.

Technical information about 'Naltrexone'

Definition: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Chemical name: Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-

Registry Number: 16590-41-3

Descriptor UI: D009271

Alternative terms: Naltrexone; Celupan; Lacer Brand of Naltrexone Hydrochloride; Trexan; Naltrexone Hydrochloride; Hydrochloride, Naltrexone; ReVia; Schering-Plough Brand of Naltrexone Hydrochloride; Schering Plough Brand of Naltrexone Hydrochloride; Lamepro Brand of Naltrexone Hydrochloride; United Drug Brand of Naltrexone Hydrochloride; Orphan Brand of Naltrexone Hydrochloride; Nemexin; Bristol-Myers Squibb Brand of Naltrexone Hydrochloride; Bristol Myers Squibb Brand of Naltrexone Hydrochloride; Du Pont Brand of Naltrexone Hydrochloride; Nalorex; Antaxone; Pharmazam Brand of Naltrexone Hydrochloride; EN-1639A; EN 1639A; EN1639A;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Narcotic Antagonists;

Tree Number: D03.132.577.249.706.550; D03.549.686.750.550; D03.605.497.750.550; D04.615.723.795.706.550;

History Note: 86(76); was see under NALOXONE 1976-85